Companies To Watch

31. Companies To Watch: Qlaris Bio 1/4/2022

    Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.

32. Companies To Watch: Graphite Bio 11/1/2021

    Graphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.

33. Companies To Watch: Atea Pharmaceuticals 10/1/2021

    Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

34. Companies To Watch: AltruBio 9/1/2021

    AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.

35. Companies To Watch: AMO Pharma 8/2/2021

    AMO Pharma is applying “de-risked” compounds as potential medicines for rare diseases in brain development.

36. Companies To Watch: NervGen Pharma 7/1/2021

    NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

37. Companies To Watch: IM Therapeutics 6/1/2021

    Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

38. Companies To Watch: Lyra Therapeutics 5/3/2021

    Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

39. Companies To Watch: Carisma Therapeutics 4/1/2021

    Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.

40. Companies To Watch: PhaseBio 3/1/2021

    PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.